The role of microRNA in castration-resistant prostate cancer

William Thieu, Derya Tilki, Ralph W deVere White, Christopher P Evans

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: Castration-resistant prostate cancer (CRPC) has a historically low median survival rate, but recent advances and discoveries in microRNAs (miRNAs) have opened the potential for new prognostication modalities to enhance therapeutic success. As new chemotherapies and immunotherapies are developed, there is an increasing need for precision and stratification of CRPC to allow for optimization and personalization of therapy. Methods: A systematic literature review was conducted via electronic database resulting in the selection of 42 articles based on title, abstract, study format, and content by a consensus of all participating authors. Most selected articles were published between 2002 and 2013. In this review, we discuss the robustness of miRNAs as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with CRPC. Results: The associations discovered have been of interest owing to the ability to differentiate between CRPC and localized prostate cancer. With the evaluation of multiple miRNAs, it is possible to provide a profile regarding tumor characteristics. Furthermore, actions of miRNAs on CRPC tumor cells have the ability to suppress metastatic phenotypes. Conclusion: miRNAs may have a growing role in CRPC prognostication and may potentially transform into a therapeutic potential.

Original languageEnglish (US)
Pages (from-to)517-523
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume32
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Castration
MicroRNAs
Prostatic Neoplasms
Immunotherapy
Neoplasms
Therapeutics
Biomarkers
Databases
Phenotype
Drug Therapy

Keywords

  • Castration-resistant prostate cancer
  • MicroRNA
  • Review

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Medicine(all)

Cite this

The role of microRNA in castration-resistant prostate cancer. / Thieu, William; Tilki, Derya; deVere White, Ralph W; Evans, Christopher P.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 32, No. 5, 2014, p. 517-523.

Research output: Contribution to journalArticle

@article{3a8717b5f7464ce0a1e2f3b55885648c,
title = "The role of microRNA in castration-resistant prostate cancer",
abstract = "Introduction: Castration-resistant prostate cancer (CRPC) has a historically low median survival rate, but recent advances and discoveries in microRNAs (miRNAs) have opened the potential for new prognostication modalities to enhance therapeutic success. As new chemotherapies and immunotherapies are developed, there is an increasing need for precision and stratification of CRPC to allow for optimization and personalization of therapy. Methods: A systematic literature review was conducted via electronic database resulting in the selection of 42 articles based on title, abstract, study format, and content by a consensus of all participating authors. Most selected articles were published between 2002 and 2013. In this review, we discuss the robustness of miRNAs as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with CRPC. Results: The associations discovered have been of interest owing to the ability to differentiate between CRPC and localized prostate cancer. With the evaluation of multiple miRNAs, it is possible to provide a profile regarding tumor characteristics. Furthermore, actions of miRNAs on CRPC tumor cells have the ability to suppress metastatic phenotypes. Conclusion: miRNAs may have a growing role in CRPC prognostication and may potentially transform into a therapeutic potential.",
keywords = "Castration-resistant prostate cancer, MicroRNA, Review",
author = "William Thieu and Derya Tilki and {deVere White}, {Ralph W} and Evans, {Christopher P}",
year = "2014",
doi = "10.1016/j.urolonc.2013.11.004",
language = "English (US)",
volume = "32",
pages = "517--523",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The role of microRNA in castration-resistant prostate cancer

AU - Thieu, William

AU - Tilki, Derya

AU - deVere White, Ralph W

AU - Evans, Christopher P

PY - 2014

Y1 - 2014

N2 - Introduction: Castration-resistant prostate cancer (CRPC) has a historically low median survival rate, but recent advances and discoveries in microRNAs (miRNAs) have opened the potential for new prognostication modalities to enhance therapeutic success. As new chemotherapies and immunotherapies are developed, there is an increasing need for precision and stratification of CRPC to allow for optimization and personalization of therapy. Methods: A systematic literature review was conducted via electronic database resulting in the selection of 42 articles based on title, abstract, study format, and content by a consensus of all participating authors. Most selected articles were published between 2002 and 2013. In this review, we discuss the robustness of miRNAs as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with CRPC. Results: The associations discovered have been of interest owing to the ability to differentiate between CRPC and localized prostate cancer. With the evaluation of multiple miRNAs, it is possible to provide a profile regarding tumor characteristics. Furthermore, actions of miRNAs on CRPC tumor cells have the ability to suppress metastatic phenotypes. Conclusion: miRNAs may have a growing role in CRPC prognostication and may potentially transform into a therapeutic potential.

AB - Introduction: Castration-resistant prostate cancer (CRPC) has a historically low median survival rate, but recent advances and discoveries in microRNAs (miRNAs) have opened the potential for new prognostication modalities to enhance therapeutic success. As new chemotherapies and immunotherapies are developed, there is an increasing need for precision and stratification of CRPC to allow for optimization and personalization of therapy. Methods: A systematic literature review was conducted via electronic database resulting in the selection of 42 articles based on title, abstract, study format, and content by a consensus of all participating authors. Most selected articles were published between 2002 and 2013. In this review, we discuss the robustness of miRNAs as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with CRPC. Results: The associations discovered have been of interest owing to the ability to differentiate between CRPC and localized prostate cancer. With the evaluation of multiple miRNAs, it is possible to provide a profile regarding tumor characteristics. Furthermore, actions of miRNAs on CRPC tumor cells have the ability to suppress metastatic phenotypes. Conclusion: miRNAs may have a growing role in CRPC prognostication and may potentially transform into a therapeutic potential.

KW - Castration-resistant prostate cancer

KW - MicroRNA

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84902457465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902457465&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2013.11.004

DO - 10.1016/j.urolonc.2013.11.004

M3 - Article

C2 - 24935732

AN - SCOPUS:84902457465

VL - 32

SP - 517

EP - 523

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 5

ER -